Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 20;111(3):881–890. doi: 10.1111/cas.14295

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Overexpression of TRIM44 was associated with cancer‐specific and overall survival in patients with renal cell carcinoma (RCC). A, B, Oncomine data showing TRIM44 overexpression in RCC samples. C‐F, Representative images of immunohistochemistry. C, Anti–TRIM44 immunostaining of clear cell carcinoma showing intensity score 2+. D, Anti–TRIM44 immunostaining of clear cell carcinoma showing intensity score 1+. E, Anti–TRIM44 immunostaining of clear cell carcinoma showing intensity score 0. F, Negative control (breast cancer tissue, rabbit immunogloblin G antibody). G, Positive control (breast cancer tissue). Scale bar = 100 μm, respectively. H, Cancer‐specific survival of patients with RCC. Patients with positive TRIM44 immunoreactivity showed poor prognosis (log‐rank test; P = .019)